利妥昔单抗对比硫唑嘌呤用于抗中性粒细胞胞质抗体相关血管炎维持缓解治疗(RITAZAREM):一项随机对照试验的研究方案
RITAZAREM是一项国际多中心开放标签随机对照试验,旨在证明对经利妥昔单抗诱导缓解的复发性AAV患者,重复静脉利妥昔单抗在预防复发方面优于每日口服硫唑嘌呤。患者复发时入组并接受利妥昔单抗联合糖皮质激素诱导,4个月内疾病控制者按1:1随机接受利妥昔单抗(每4个月1000 mg,共5次)或硫唑嘌呤(2 mg/kg/日)维持治疗,至少随访36个月,主要结局为至疾病复发时间,估计需招募190例以确保至少160例随机化。
要点
- RITAZAREM trial compares rituximab vs azathioprine for relapse prevention in AAV after rituximab induction.
- Rituximab arm: 1000 mg every 4 months for five doses; azathioprine arm: 2 mg/kg/day.
- Primary outcome is time to disease relapse; minimum follow-up 36 months.
核心结论
- RITAZAREM试验将提供利妥昔单抗作为AAV缓解诱导治疗后比较两种维持策略的最大试验数据集,并探索延长B细胞清除是否可在停用免疫抑制治疗后获得持续无治疗缓解。
研究设计与样本
- RITAZAREM是一项国际、多中心、开放标签、随机对照试验,旨在证明重复静脉利妥昔单抗相比每日口服硫唑嘌呤在复发性AAV患者中预防复发的优越性。
- 患者在复发时入组,接受利妥昔单抗和糖皮质激素诱导治疗;若4个月时疾病控制,按1:1比例随机接受利妥昔单抗(每4个月1000 mg,共5次)或硫唑嘌呤(2 mg/kg/日)维持治疗。
- 患者至少随访36个月,主要结局为至疾病复发时间;估计需招募190例以确保至少160例被随机化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rituximab is effective as therapy for induction of remission in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the effect of rituximab is not sustained, and subsequent relapse rates are high, especially in patients with a history of relapse. There is a need to identify whether maintenance therapy with rituximab is superior to the current standard of azathioprine or methotrexate for prevention of relapse following induction with rituximab. METHODS/DESIGN: RITAZAREM is an international, multicenter, open-label, randomized controlled trial designed to demonstrate the superiority of repeated doses of intravenous rituximab compared to daily orally administered azathioprine as a relapse prevention strategy in patients with AAV with relapsing disease who undergo induction of remission with rituximab. Patients with AAV will be recruited at the time of relapse and will receive rituximab and glucocorticoid induction therapy. If the disease is controlled by 4 months, patients will be randomized in a 1:1 ratio to receive rituximab (1000 mg every 4 months for five doses) or azathioprine (2 mg/kg/day) as maintenance therapy. Patients will be followed for a minimum of 36 months. The primary outcome is the time to disease relapse. It is estimated that 190 patients will need to be recruited to ensure that at least 160 are randomized. DISCUSSION: The RITAZAREM trial will provide the largest trial dataset for the use of rituximab as remission-induction therapy for patients with AAV comparing two remission-maintenance strategies following induction with rituximab, and explore whether prolonged B-cell depletion leads to sustained treatment-free remissions after discontinuation of immunosuppressive therapy. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01697267 . Registered on 31 August 2012.
引用
- Gopaluni S, Smith RM, Lewin M, et al. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials. 2017. PMID: 28270229. doi:10.1186/s13063-017-1857-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。